Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ... (9.6 and 9.4 eye chart letters ...

A study has shown that Roche's diabetic macular oedema (DME ... read about two and a half more lines (12.3 letters) on an eye chart, a result that was consistent with the phase 3 studies that ...

The T&E regimens showed 46% reduction in the number of clinic ... eye. If both eyes were eligible, the eye with worse VA was selected as the study eye. Patients were excluded if they showed structural ...

Methods: A retrospective chart review of patients with molecularly ... of eyes. The extent of macular involvement remained stable over the follow-up duration for all but one eye, where there was ...

Objectives To evaluate the cost-effectiveness of immediate treatment with ranibizumab in patients with neovascular age-related macular degeneration (nAMD ... levels of visual acuity in the better ...